Immunotherapy in Melanoma | Specialty

Targeted Immunotherapy in Cancer

July 18th 2014

Future Role of Immunotherapy in Cancer

July 18th 2014

PD-L1 Inhibition With MPDL3280A in Bladder Cancer

July 18th 2014

Adjuvant Ipilimumab in High-Risk Melanoma

July 18th 2014

Checkpoint Inhibitor Combination Strategies

July 18th 2014

Future Role of Checkpoint Inhibitors in Melanoma

July 18th 2014

Checkpoint Inhibitors in Metastatic Melanoma

July 18th 2014

Introduction: Immunotherapy Research Milestones

July 18th 2014

Dabrafenib/Trametinib Extends OS Versus Vemurafenib in Phase III Melanoma Trial

July 18th 2014

A phase III study comparing trametinib (Mekinist) plus dabrafenib (Tafinlar) with single-agent vemurafenib (Zelboraf) has been stopped early following a positive interim analysis

Immunotherapy Branches Out

July 18th 2014

Immunotherapy agents are delivering impressive results in a broad range of tumor types, reinforcing the excitement in research and investment circles for anticancer strategies that actively harness the immune system

Vemurafenib/Cobimetinib Extends PFS in Phase III Melanoma Study

July 14th 2014

The combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib significantly improved PFS compared with vemurafenib alone for patients with untreated BRAFV600-mutated advanced melanoma.

Dr. Puzanov on T-VEC in Combination with Ipilimumab for Melanoma Treatment

July 9th 2014

Igor Puzanov, MD, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the rationale behind a phase Ib study to evaluate the efficacy and safety of T-VEC and ipilimumab in previously untreated, unresected stage IIIB-IV melanoma.

Nivolumab, Alectinib Gain Approvals in Japan

July 7th 2014

The PD-1 inhibitor nivolumab and the second-generation ALK inhibitor alectinib have each gained their first approvals as treatments for patients in Japan.

Frontline Nivolumab Improves Survival in Phase III Melanoma Study

June 25th 2014

Frontline treatment with the anti-PD-1 agent nivolumab significantly extended overall survival when compared with dacarbazine for patients with metastatic or unresectable melanoma.

Checkpoint Agents Are Shifting Paradigms Toward Immunotherapy

June 16th 2014

The concept of manipulating the immune system to treat cancer has experienced waxing and waning levels of enthusiasm over decades of clinical investigation.

Dr. Sznol on Combining Nivolumab and Ipilimumab for the Treatment of Advanced Melanoma

June 10th 2014

Mario Sznol, MD, professor, Internal Medicine, Yale Cancer Center, discusses a phase I trial that examined the combination of nivolumab and ipilimumab for the treatment of advanced melanoma.

2014 NCCN Guideline Updates: Experts Highlight New Recommendations for Clinical Practice

June 6th 2014

At the recent National Comprehensive Cancer Network (NCCN) 19th Annual Conference, experts discussed this year's updates to the NCCN Clinical Practice Guidelines in Oncology. The meeting also included reviews of NCCN Task Force reports on issues in supportive care. We asked eleven NCCN panel members to select the most significant updates and insights presented at the conference.

Dr. Wolchok on Ipilimumab After Complete Resection of Stage III Melanoma

June 5th 2014

Jedd D. Wolchok, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, Giant of Cancer Care, discusses the initial efficacy and safety results from the EORTC 18071 phase III trial, which looked at ipilimumab versus placebo after complete resection of stage III melanoma.

Follow-up of Concurrent Immunotherapies Shows Unprecedented Survival Rate in Melanoma

June 3rd 2014

Long-term follow-up results demonstrated nearly doubled median OS with the combination of ipilimumab and nivolumab compared with either agent alone.

T-VEC Combinations, Monotherapy Intriguing in Unresectable Melanoma

June 2nd 2014

The intratumoral injection talimogene laherparepvec demonstrated promise in combinations and utility as a monotherapy in certain subsets of patients with unresectable melanoma.